Last Updated on October 14, 2024 by The Health Master
Granules India Limited, a pharmaceutical company, has completed the U.S. Food and Drug Administration’s (USFDA) Pre-Approval Inspection (PAI) and GMP audit for their facility (Unit IV) at Visakhapatnam in Andhra Pradesh.
The company said its facility at Jeedimetla (Hyderabad) also completed the USFDA’s surveillance inspection.
“The Vizag facility was inspected by a USFDA team from June 26 to 30, while the Jeedimetla facility completed the process from June 19 to 23.
The successful completion of the inspection by the FDA reflects our commitment to quality and compliance,” Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, said.
USFDA completes inspection at Ajanta Pharma with zero observations: Gujarat
USFDA concludes inspection at Zydus with zero observation
USFDA completes inspection of Dr Reddy’s with zero observation
USFDA issues Form 483 with 11 observations IPCA Labs: Ratlam
USFDA issues Form 483 with 4 observations to Aurobindo Pharma
USFDA issues Form 483 with zero observations to Pharma MSMEs: Gujarat
Hyderabad Pharma City: A Thriving Hub for Pharma Industry
DTAB: Examination of RMP requirement for sale of Cough Syrups
NPPA fixed Ceiling price of 2 scheduled formulations: June 2023
CDSCO orders transfer of 33 Deputy Drugs Controllers: List here
Explosion in Pharma Company: Andhra Pradesh
NPPA fixed retail price of 51 formulations: June 2023
FDA cancels licences of 38 Nashik chemists in a year
DTAB upholds prohibition on FDC of Vitamin B1, B6, and B12
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
